

PRESS RELEASE

Indoco's operating margins grow by 18% at Rs. 38.5 Crores

Mumbai, May 30, 2018: Indoco Remedies posted revenues of ₹ 258.9 crore during the fourth quarter of FY 2017-18, as against ₹ 265.5 crores, for the same quarter last year. The Company's Profit After Tax is at ₹ 20.5 crores, as against ₹ 17.9 crores, for the same quarter last year.

Commenting on the 4th quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "Operating margins for the quarter grew at 18% and EBIDTA was at 19.1%. While the Indian Business registered a double digit growth, the Regulated Markets did not perform as expected due to regulatory issues. However, Emerging Markets showed good growth at 24%".

For the quarter ended March'18, the financials are as under:

(₹ in Crores)

Particulars	Jan'18-Mar'18	Jan'17-Mar'17
Net Revenue	258.9	265.5
EBIDTA	49.4	32.6
Operating Profit	38.5	32.6
Profit After Tax	20.5	17.9
EPS (Face value ₹ 2/-) (Not annualized)	2.22	1.95

For the year ended March'18, the financials are as under:

Particulars	Apr'17-Mar'18	Apr'16-Mar'17
Net Revenue	1017.3	1066.6
EBIDTA	134.9	156.6
Operating Profit	97.1	138.9
Profit After Tax	41.2	77.4
EPS (Face value ₹ 2/-) (Not annualized)	4.47	8.40

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 165 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 Doctors, including various Specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com